DE69812941D1 - Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr - Google Patents

Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr

Info

Publication number
DE69812941D1
DE69812941D1 DE69812941T DE69812941T DE69812941D1 DE 69812941 D1 DE69812941 D1 DE 69812941D1 DE 69812941 T DE69812941 T DE 69812941T DE 69812941 T DE69812941 T DE 69812941T DE 69812941 D1 DE69812941 D1 DE 69812941D1
Authority
DE
Germany
Prior art keywords
microparticles
immune defense
stimulate immune
adsorbed antigen
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69812941T
Other languages
English (en)
Other versions
DE69812941T2 (de
Inventor
Derek O'hagan
Nest Gary Van
S Ott
John Barackman
Jina Kazzaz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of DE69812941D1 publication Critical patent/DE69812941D1/de
Publication of DE69812941T2 publication Critical patent/DE69812941T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DE69812941T 1997-01-30 1998-01-29 Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr Expired - Lifetime DE69812941T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3631697P 1997-01-30 1997-01-30
US36316P 1997-01-30
US6974997P 1997-12-16 1997-12-16
US69749P 1997-12-16
PCT/US1998/001738 WO1998033487A1 (en) 1997-01-30 1998-01-29 Use of microparticles with adsorbed antigen to stimulate immune responses

Publications (2)

Publication Number Publication Date
DE69812941D1 true DE69812941D1 (de) 2003-05-15
DE69812941T2 DE69812941T2 (de) 2004-02-05

Family

ID=26713053

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69812941T Expired - Lifetime DE69812941T2 (de) 1997-01-30 1998-01-29 Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr

Country Status (13)

Country Link
US (2) US7597908B2 (de)
EP (1) EP0991403B1 (de)
JP (2) JP5037747B2 (de)
AT (1) ATE235890T1 (de)
AU (1) AU747577B2 (de)
CA (1) CA2279204C (de)
DE (1) DE69812941T2 (de)
DK (1) DK0991403T3 (de)
ES (1) ES2195317T3 (de)
HK (1) HK1023507A1 (de)
NZ (1) NZ337054A (de)
PT (1) PT991403E (de)
WO (1) WO1998033487A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100372375B1 (ko) 1993-12-23 2003-04-21 머클한스피터 면역반응의강화방법
US6884435B1 (en) 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US20040202680A1 (en) * 1997-01-30 2004-10-14 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
ATE235890T1 (de) 1997-01-30 2003-04-15 Chiron Corp Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
ES2260923T3 (es) * 1998-07-29 2006-11-01 Chiron Corporation Micorparticulas con superficies adsorbentes, procedimientos de fabricacion y uso de las mismas.
JP2002537102A (ja) * 1999-02-26 2002-11-05 カイロン コーポレイション 吸着された高分子および微粒子を有するミクロエマルジョン
JP2002538195A (ja) * 1999-03-08 2002-11-12 パウダージェクト リサーチ リミテッド 生物活性化合物の持続放出用の無針注射器を使用する微粒子製剤の送達
US7713739B1 (en) 2000-11-17 2010-05-11 Novartis Vaccines And Diagnostics, Inc. Microparticle-based transfection and activation of dendritic cells
GB0000001D0 (en) * 2000-01-05 2000-02-23 Du Pont Uk Pharmaceutical compositions and their preparation
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
GB0006770D0 (en) * 2000-03-22 2000-05-10 Secr Defence Vaccine composition
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US20040022814A1 (en) * 2000-06-15 2004-02-05 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
AUPR011700A0 (en) * 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
SG137691A1 (en) * 2000-09-28 2007-12-28 Chiron Corp Microparticles for delivery of the heterologous nucleic acids
WO2002026212A2 (en) 2000-09-28 2002-04-04 Chiron Corporation Microparticle compositions and methods for the manufacture thereof
US6887857B2 (en) 2001-04-27 2005-05-03 Scimed Life Systems, Inc. Microparticle protection of therapeutic agents
DE10125731A1 (de) * 2001-05-17 2003-03-06 A I D Autoimmun Diagnostika Gm Darreichungsform von immunologischen Wirkstoffen
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US7368102B2 (en) 2001-12-19 2008-05-06 Nektar Therapeutics Pulmonary delivery of aminoglycosides
EP1531796B1 (de) * 2002-02-20 2016-09-28 GlaxoSmithKline Biologicals SA Mikropartikel mit adsorbierten polypeptidhaltigen molekülen
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
EP1565583A4 (de) * 2002-10-07 2007-11-21 Novartis Vaccines & Diagnostic Hiv-vakzine-formulierungen
DE60332477D1 (de) 2002-11-15 2010-06-17 Novartis Vaccines & Diagnostic Unerwartete oberflächenproteine in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CA2511512C (en) 2002-12-27 2013-10-29 Chiron Corporation Immunogenic compositions containing phospholipid
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
PT1631264E (pt) 2003-06-02 2009-11-03 Novartis Vaccines & Diagnostic Composições imunogénicas à base de micropartículas biodegradáveis que compreendem um toxóide de difteria e do tétano
FR2859909B1 (fr) * 2003-09-22 2007-09-07 Biomerieux Sa Procede de preparation de microparticules bioresorbables, microparticules obtenues et utilisation
EP1812056B1 (de) 2004-11-15 2013-08-07 Novartis Vaccines and Diagnostics, Inc. Immunogene zusammensetzungen, welche ein anthrax antigen, mikropartikel aus biologisch abbaubaren polymeren, und ein nukleinsäurehältiges adjuvans beinhalten.
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
FR2893254B1 (fr) * 2005-11-14 2007-12-21 Biomerieux Sa Composition comprenant un vecteur synthetique colloidal bioresorbable et un vecteur viral et son utilisation prophylactique, therapeutique et diagnostique.
CA2643322C (en) 2006-02-24 2015-07-21 Novartis Ag Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions
EP2244695A1 (de) 2007-12-07 2010-11-03 Novartis AG Zusammensetzungen zur induktion von immunantworten
KR20130121699A (ko) 2010-05-28 2013-11-06 테트리스 온라인, 인코포레이티드 상호작용 혼성 비동기 컴퓨터 게임 기반구조
CN103796639B (zh) 2011-07-06 2017-05-31 诺华股份有限公司 阳离子水包油乳液
JP6059220B2 (ja) 2011-07-06 2017-01-18 ノバルティス アーゲー 核酸を含む水中油型エマルジョン
JP6205360B2 (ja) * 2011-08-22 2017-09-27 ナノバイオ コーポレーション 単純ヘルペスウイルスのナノエマルジョンワクチン
US9782520B2 (en) 2011-09-26 2017-10-10 BioSpheres, Inc. Reduction of implant infection via tunable stimulation of localized adaptive immune response
WO2019169370A1 (en) * 2018-03-02 2019-09-06 University Of The Sciences Polymer compositions for storage and release of polypeptides
EP3581201A1 (de) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 polypeptide und verwendungen davon

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4413057A (en) 1980-04-14 1983-11-01 Merck & Co., Inc. Group B streptococcal capsular polysaccharides
US4534996A (en) 1981-03-30 1985-08-13 California Institute Of Technology Hybrid microspheres
JPS6150378A (ja) * 1984-08-20 1986-03-12 Mitsui Toatsu Chem Inc 非晶質太陽電池の製法
US5151266A (en) * 1985-08-20 1992-09-29 Neorx Corporation Use of anionic detergents with conjugates of monoclonal or polyclonal antibodies
US5151225A (en) 1989-05-01 1992-09-29 Hoover Treated Wood Products, Inc. Flame retardant composition and method for treating wood
WO1990014357A1 (en) 1989-05-19 1990-11-29 Genentech, Inc. Her2 extracellular domain
US5010183A (en) 1989-07-07 1991-04-23 Macfarlane Donald E Process for purifying DNA and RNA using cationic detergents
ES2166352T3 (es) 1989-08-04 2002-04-16 Schering Ag Dominio externo de c-erbb-2:gp75.
MX9204376A (es) 1991-07-25 1993-02-01 Idec Pharma Corp Composiciones y metodos para inducir respuestas citotoxicas de los linfocitos t.
ATE152915T1 (de) 1991-11-29 1997-05-15 Viagene Inc Immuntherapeutische vektorkonstrukte gegen krebs
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
FR2695563B1 (fr) 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
JPH08505625A (ja) * 1993-01-11 1996-06-18 ダナ−ファーバー キャンサー インスティチュート 細胞毒性ｔリンパ球応答の誘導
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5869445A (en) 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
GB9311454D0 (en) * 1993-06-03 1993-07-21 Agricultural & Food Res Pharmaceutical compositions
US5643605A (en) 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
US5902565A (en) 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
WO1995024929A2 (en) 1994-03-15 1995-09-21 Brown University Research Foundation Polymeric gene delivery system
WO1995032000A1 (en) 1994-05-20 1995-11-30 Microgenesys, Inc. Hiv polyprotein immunogens
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5827531A (en) 1994-12-02 1998-10-27 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microcapsules and methods for making
JPH10511957A (ja) * 1995-01-05 1998-11-17 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ ミシガン 表面改質ナノ微粒子並びにその製造及び使用方法
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
WO1996026277A1 (en) * 1995-02-24 1996-08-29 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US5714354A (en) 1995-06-06 1998-02-03 American Home Products Corporation Alcohol-free pneumococcal polysaccharide purification process
GB9514285D0 (en) * 1995-07-13 1995-09-13 Univ Nottingham Polymeric lamellar substrate particles for drug delivery
US5630922A (en) 1995-12-26 1997-05-20 Ppg Industries, Inc. Electrodepositable coating composition containing diorganotin dicarboxylates
WO1997024447A1 (en) 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
GB9619002D0 (en) 1996-09-11 1996-10-23 Oxford Biosciences Ltd Particle delivery
US5783567A (en) 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
ATE235890T1 (de) 1997-01-30 2003-04-15 Chiron Corp Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr
US6884435B1 (en) 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6086901A (en) 1997-12-16 2000-07-11 Chiron Corporation Use of microparticles combined with submicron oil-in-water emulsions
JP4658423B2 (ja) 1999-08-03 2011-03-23 ザ オハイオ ステイト ユニバーシティ Ｈｅｒ−２タンパク質に対する免疫反応性を増強するためのポリペプチドおよびポリヌクレオチド
US20040022814A1 (en) 2000-06-15 2004-02-05 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
WO2002026212A2 (en) 2000-09-28 2002-04-04 Chiron Corporation Microparticle compositions and methods for the manufacture thereof
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.

Also Published As

Publication number Publication date
DK0991403T3 (da) 2003-07-28
AU6255798A (en) 1998-08-25
EP0991403A1 (de) 2000-04-12
CA2279204C (en) 2005-11-15
ES2195317T3 (es) 2003-12-01
DE69812941T2 (de) 2004-02-05
US20030049298A1 (en) 2003-03-13
ATE235890T1 (de) 2003-04-15
JP5037747B2 (ja) 2012-10-03
EP0991403B1 (de) 2003-04-02
HK1023507A1 (en) 2000-09-15
US7597908B2 (en) 2009-10-06
US20100021548A1 (en) 2010-01-28
PT991403E (pt) 2003-08-29
AU747577B2 (en) 2002-05-16
JP2001511148A (ja) 2001-08-07
CA2279204A1 (en) 1998-08-06
NZ337054A (en) 2001-03-30
JP2009102338A (ja) 2009-05-14
WO1998033487A1 (en) 1998-08-06

Similar Documents

Publication Publication Date Title
ATE235890T1 (de) Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr
DE3667378D1 (de) Verwendung von n-(4-phenoxy-2,6-diisopropylphenyl)-n'-tert.butylthioharnstoff zur bekaempfung von weissen fliegen.
DE3884190D1 (de) Behandlung von unterirdischen Formationen mit spät reagierenden Quervernetzenden Gelen.
DE69720190D1 (de) Implantierbares system mit verzögerter freisetzung von leuprolid
DE69824735D1 (de) Implantierbarer stimulator mit effizientem ausgangsgenerator
DE69827420D1 (de) Herzschrittmacher mit variabler Stimulationsenergie
DE69411692D1 (de) Mittel zur Förderung der Proliferationen von Bifidobacterium
DE69826079D1 (de) Lokalisator von elektrisch leitenden objekten
BR8902170A (pt) Aparelho de iluminacao e refletor
DE3872754D1 (de) Nachweis von antikoerpern humaner immundefizienz-viren.
DE3883282D1 (de) Silikonklebstoff und organische klebstoffemulsion.
DE68906822D1 (de) Spulentraeger mit heizspule.
NO902696D0 (no) Ny familie av modifiserte hoeyaffinitetsantistoff for kreftbehandling.
DE69034090D1 (de) Halbleitervorrichtung zur Detektion oder Emission von Magnetfeldlinien oder Licht
ATE114713T1 (de) Biomasse zur produktion von virus/virusantigen.
DE69835016D1 (de) Verwendung von midkin oder von anti-midkin antikörper
DE69008535D1 (de) Humane antigammainterferonantikörper, welche detektiert und geklärt sind mit verwendung von synthetischen peptiden.
DE68918934D1 (de) Einrichtung zur Beleuchtung und Heizung.
DE69001615D1 (de) Mit niederfrequenter spannung gespeistes elektromagnetisches induktionsheizgeraet.
DE3876213D1 (de) Dimerisierung von acrylnitril.
DE69836056D1 (de) Prozessor mit verringerter Zahl von bedingten Befehlen
DE68910529D1 (de) Von mikrowellen angetriebene heizkammer.
DE69732497D1 (de) Bremsvorrichtung mit zone von kontrolierter zerbrechlichkeit
FI890183A (fi) Anordning foer roerelse i en roerformad ledning.
DE69823410D1 (de) Herzschrittmacher mit verbesserter Hysterese

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US